These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 27417252)

  • 1. Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-γ-dependent mechanism.
    Matsunaga T; Suzuki A; Kezuka C; Okumura N; Iguchi K; Inoue I; Soda M; Endo S; El-Kabbani O; Hara A; Ikari A
    Chem Biol Interact; 2016 Aug; 256():142-53. PubMed ID: 27417252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide confers cisplatin resistance in human lung cancer cells through upregulation of aldo-keto reductase 1B10 and proteasome.
    Matsunaga T; Yamaji Y; Tomokuni T; Morita H; Morikawa Y; Suzuki A; Yonezawa A; Endo S; Ikari A; Iguchi K; El-Kabbani O; Tajima K; Hara A
    Free Radic Res; 2014 Nov; 48(11):1371-85. PubMed ID: 25156503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through up-regulating aldo-keto reductase 1B10.
    Morikawa Y; Kezuka C; Endo S; Ikari A; Soda M; Yamamura K; Toyooka N; El-Kabbani O; Hara A; Matsunaga T
    Chem Biol Interact; 2015 Mar; 230():30-9. PubMed ID: 25686905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiological roles of autophagy and aldo-keto reductases in development of doxorubicin resistance in gastrointestinal cancer cells.
    Matsunaga T; Kawabata S; Yanagihara Y; Kezuka C; Kato M; Morikawa Y; Endo S; Chen H; Iguchi K; Ikari A
    Chem Biol Interact; 2019 Dec; 314():108839. PubMed ID: 31563593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers.
    Matsunaga T; Hojo A; Yamane Y; Endo S; El-Kabbani O; Hara A
    Chem Biol Interact; 2013 Feb; 202(1-3):234-42. PubMed ID: 23165153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of the aldo-keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms.
    Matsunaga T; Yamane Y; Iida K; Endo S; Banno Y; El-Kabbani O; Hara A
    Anticancer Drugs; 2011 Jun; 22(5):402-8. PubMed ID: 21317765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of aldo-keto reductases 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance.
    Matsunaga T; Saito H; Endo S; Iguchi K; Soda M; El-Kabbani O; Hara A; Ikari A
    Free Radic Res; 2016 Dec; 50(12):1296-1308. PubMed ID: 27629782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect and mechanism of peroxisome proliferator-activated receptor-γ on the drug resistance of the U-87 MG/CDDP human malignant glioma cell line.
    Han S; Lv X; Wang Y; Gong H; Zhang C; Tong A; Zhang B; Yao H
    Mol Med Rep; 2015 Aug; 12(2):2239-46. PubMed ID: 25891367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure to 9,10-phenanthrenequinone accelerates malignant progression of lung cancer cells through up-regulation of aldo-keto reductase 1B10.
    Matsunaga T; Morikawa Y; Haga M; Endo S; Soda M; Yamamura K; El-Kabbani O; Tajima K; Ikari A; Hara A
    Toxicol Appl Pharmacol; 2014 Jul; 278(2):180-9. PubMed ID: 24813866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of cisplatin resistance in breast cancer MCF7 cells by up-regulating aldo-keto reductase 1C3 expression, glutathione synthesis and proteasomal proteolysis.
    Kobayashi M; Yonezawa A; Takasawa H; Nagao Y; Iguchi K; Endo S; Ikari A; Matsunaga T
    J Biochem; 2022 Jan; 171(1):97-108. PubMed ID: 34676395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldo-keto reductase 1B10 protects human colon cells from DNA damage induced by electrophilic carbonyl compounds.
    Zu X; Yan R; Pan J; Zhong L; Cao Y; Ma J; Cai C; Huang D; Liu J; Chung FL; Liao DF; Cao D
    Mol Carcinog; 2017 Jan; 56(1):118-129. PubMed ID: 26969882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.
    Endo S; Xia S; Suyama M; Morikawa Y; Oguri H; Hu D; Ao Y; Takahara S; Horino Y; Hayakawa Y; Watanabe Y; Gouda H; Hara A; Kuwata K; Toyooka N; Matsunaga T; Ikari A
    J Med Chem; 2017 Oct; 60(20):8441-8455. PubMed ID: 28976752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
    Zhang W; Li H; Yang Y; Liao J; Yang GY
    Cancer Lett; 2014 Dec; 355(2):273-80. PubMed ID: 25304374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
    Chung YT; Matkowskyj KA; Li H; Bai H; Zhang W; Tsao MS; Liao J; Yang GY
    Mod Pathol; 2012 May; 25(5):758-66. PubMed ID: 22222635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
    Takemura M; Endo S; Matsunaga T; Soda M; Zhao HT; El-Kabbani O; Tajima K; Iinuma M; Hara A
    J Nat Prod; 2011 May; 74(5):1201-6. PubMed ID: 21561086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
    Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway.
    Nishinaka T; Miura T; Sakou M; Hidaka C; Sasaoka C; Okamura A; Okamoto A; Terada T
    Chem Biol Interact; 2015 Jun; 234():274-81. PubMed ID: 25463304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HtrA1 Down-regulation Induces Cisplatin Resistance in Colon Cancer by Increasing XIAP and Activating PI3K/Akt Pathway.
    Xiong Z; Fu Z; Shi J; Jiang X; Wan H
    Ann Clin Lab Sci; 2017 May; 47(3):264-270. PubMed ID: 28667026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of aldo-keto reductase AKR1B10 gene expression: involvement of transcription factor Nrf2.
    Nishinaka T; Miura T; Okumura M; Nakao F; Nakamura H; Terada T
    Chem Biol Interact; 2011 May; 191(1-3):185-91. PubMed ID: 21277289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
    Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
    Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.